CLX

Business Profile & Competitive Position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, posting fiscal 2026 net sales of $6.7 billion with roughly 9,200 employees operating in approximately 25 countries and selling in about 95 markets. Its shelf-stable consumer brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while the professional arm sells under Purell, CloroxPro, and Clorox Healthcare.

The economic moat here is primarily brand-based: repeat purchases of cleaning, cat litter, charcoal, and salad dressing create a recurring-revenue stream and long-standing retail shelf relationships. That said, the numbers temper the picture. Its net margin is 8.7%, which is serviceable but not especially wide for a staples business, and its ROE is -1893.5%, an extreme negative figure that reflects a deeply negative shareholders’ equity position rather than sustainable capital returns. In other words, Clorox owns strong household brands, but its balance-sheet structure means ROE is not a useful measure of competitive quality right now.

Another structural consideration is customer concentration. In fiscal 2026, Walmart alone accounted for 26% of consolidated net sales, and the five largest customers represented about half of net sales. That concentration gives major retailers meaningful leverage over pricing and shelf space, which can compress margins even when brand equity remains intact.

Financial Posture

Clorox currently trades at $87.09, carries a $10.5 billion market cap, and trades at a P/E of 18.1. With fiscal 2026 net sales of $6.7 billion, the stock is priced at roughly 1.6 times sales. Its beta is 0.57, consistent with a defensive, lower-volatility consumer staples stock. The RSI stands at 53.3, a neutral reading, while the 50-day EMA is $89.21—meaning the price is currently slightly below that intermediate-term moving average.

The profitability picture is mixed. The 8.7% net margin shows the company is still converting sales into profit, but the -1893.5% ROE underscores that equity has been eroded, likely by a combination of accumulated losses, share repurchases, and acquisition activity. The market is therefore valuing Clorox off earnings and cash flow rather than balance-sheet equity. With a low-beta profile and a staples business model, the valuation arguably reflects both defensive demand and the near-term margin/ERP execution risks documented in the company’s filings.

Strategic Priorities & Outlook

Clorox’s most recent 10-K outlines a clear set of near-term priorities. The company is executing its IGNITE strategy around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation. The stated goal is to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. Clorox is also investing in brand strength, strategic digital capabilities, and a streamlined operating model to build a more resilient company and deliver consistent, profitable growth.

Portfolio strategy centers on health and hygiene expansion. The April 2026 acquisition of GOJO Industries broadened Clorox’s health and hygiene portfolio and strengthened its business-to-business presence, especially in professional and institutional markets. Meanwhile, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, after which Clorox purchased P&G’s 20% interest; Glad retained core intellectual property licenses on a royalty-free basis.

These initiatives are unfolding against a soft fiscal 2026 backdrop, when organic sales and earnings declined and diluted EPS fell 26%. Part of that decline was attributed to macroeconomic headwinds and the timing of the ERP transition, which had pulled some sales forward into fiscal 2025.

Macro & Geopolitical Exposure

As a Household & Personal Products company, Clorox is exposed to input costs tied to petrochemicals, resins, paper pulp, packaging materials, and transportation fuel. Any sustained move in oil, natural gas, or recycled resin prices can matter for margins, especially when retailers resist pass-through pricing.

The industry also faces regulatory exposure. Disinfectant and cleaning products are subject to EPA and FTC scrutiny around efficacy claims, labeling, and chemical safety, while packaging rules increasingly target recyclability and plastic waste. Because Clorox operates in about 25 countries and sells in roughly 95 markets, currency translation and local regulations add another layer of variability.

Demand is generally defensive—households still buy bleach, litter, and trash bags in a downturn—but private-label competition can intensify when consumers trade down. The company’s heavy reliance on Walmart and other large retailers also ties it to the bargaining power of those channels, a macro-style risk that sits inside the sector rather than outside it.

Recent Developments

The recent news flow has framed Clorox as an income-oriented, beaten-down consumer name. On October 18, 2026, fool.com listed Clorox among “5 Dividend Stocks Trading Near 52-Week Lows That I'd Hold for the Next 5 Years.” The same day, defenseworld.net reported that Birch Hill Investment Advisors LLC sold 11,260 shares of The Clorox Company. Earlier in the week, on October 13, 2026, 247wallst.com cautioned that “These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise,” and fool.com separately included Clorox among “4 Beaten-Down Consumer Stocks to Buy Now” for passive income seekers.

Together, the headlines capture the current tension around the stock: it is being marketed as a defensive dividend opportunity near lows, yet some observers are questioning whether the payout ratio truly supports that narrative. The small institutional sale by Birch Hill is a datapoint, not a thesis, but it fits a broader wait-and-see sentiment around margin recovery and ERP execution.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Clorox has beaten earnings estimates six times, for a 75% beat rate, with an average earnings surprise of 9.6%. Across those quarters, the average 5-day price move after earnings has been +1.67%, classified as an upward post-earnings drift.

The most recent results show how noisy that average can be. On August 3, 2026, Clorox reported actual EPS of $1.66 against an estimate of $1.64, a 1.2% beat, and the stock rallied 6.52% the next day and 9.61% over the following five days. The prior quarter, April 30, 2026, produced a 5.8% beat ($1.64 vs. $1.55) yet the stock fell 9.67% the next day and closed the five-day window down 4.49%, suggesting that the market’s real expectation revolved around guidance or margin commentary rather than the headline EPS number.

Other recent prints reinforce that point. On February 3, 2026, Clorox missed with EPS of $1.39 versus $1.43, but the stock rose 2.43% the next day and 5.63% over five days. On November 3, 2025, a 3.9% beat ($0.85 vs. $0.818) produced a modest 1.17% next-day gain but a -4.08% five-day drift. The next scheduled report is November 2, 2026, after the close, with a consensus EPS estimate of $1.08.

For a deeper dive into how professional analysts are weighing the GOJO integration, ERP rollout, and dividend sustainability, readers should consult the full institutional verdict on the platform rather than relying on headline narratives alone.